

CONFIDENTIALITY AGREEMENT

THIS AGREEMENT is made on 8 December 2025

BETWEEN

- (1) **INTRALOT HOLDINGS UK LTD**, a company registered in England with registered number 16579703 and its registered office at 3rd Floor, 1 Ashley Road, Altrincham, Cheshire WA14 2DT, United Kingdom (the “**Buyer**”); and
- (2) **WILLIAM HILL ORGANIZATION LIMITED**, a company registered in England and Wales with registered number 00278208 and its registered office at 1 Bedford Avenue, London, WC1B 3AU One Bedford Avenue, London, WC1B (“**evoke**”).

BACKGROUND

- (A) The Buyer (a wholly owned subsidiary of Intralot S.A. Integrated Lottery Systems and Services of 19km Markopoulou Ave., Peania 190 02, Greece) has expressed an interest in a potential transaction by one or more of the Buyer’s Affiliates with evoke Plc, a company registered in Gibraltar with its registered office at Suite 601/701 Europort, Europort Road, Gibraltar, GX11 1AA (“**evoke Plc**”) relating to evoke Plc or any of its Group Companies (the “**Proposed Transaction**”).
- (B) This Agreement sets out undertakings by the Buyer about the use of Confidential Information. The Buyer is giving such undertakings in favour of evoke and evoke’s Affiliates (each of whom shall be entitled to rely upon and enforce all the terms of this Agreement), in consideration for evoke agreeing to make available Confidential Information to the Buyer and the Authorised Recipients.

AGREED TERMS

1. DEFINITIONS AND INTERPRETATION

1.1 In this Agreement, unless expressly stated otherwise:

“**Affiliates**” means, in respect of a body corporate, any subsidiary undertaking or parent undertaking of the body corporate, and any subsidiary undertaking of any such parent undertaking, in each case from time to time;

“**Authorised Recipients**” means:

- (a) the Buyer’s Affiliates;
- (b) any provider or prospective provider of debt or equity finance to the Buyer or the Buyer’s Affiliates in connection with the Proposed Transaction;
- (c) any Representatives (other than any provider or broker of warranty and indemnity insurance except with the prior written consent of evoke) of the Buyer or any person referred to in paragraphs (a) or (b) above, to the extent such Representatives are involved in the Proposed Transaction;

“**Business Day**” means a day other than a Saturday, Sunday or public holiday in the City of London;

“**Code**” means the City Code on Takeovers and Mergers, as amended from time to time;

“**Confidential Information**” means:

- (a) all business, technical, financial, operational, administrative, customer, marketing, legal, economic and other information in whatever form (including in written, oral, visual or electronic form) relating to the Group or any Group Company that is directly or indirectly disclosed on or after the date of this Agreement, to the Buyer or any of the Authorised Recipients, by evoke, its Affiliates or its or their respective Representatives in connection with the Proposed Transaction;
- (b) all information in whatever form (including in written, oral, visual or electronic form) relating to the existence, status or progress of the Proposed Transaction including the existence and contents of this Agreement and the fact that discussions and negotiations may be taking place in relation to the Proposed Transaction; and
- (c) all documents to the extent that they contain or reflect or are generated from any of the foregoing and all copies of any of the foregoing;

“**Group**” means evoke Plc and each of its subsidiary undertakings from time to time;

“**Group Company**” means any member of the Group;

“**Representatives**” means, in relation to a person, its directors, officers, employees, agents, consultants and professional advisers;

“**Restricted Persons**” means any director, officer, or Senior Employee of any Group Company or any of evoke’s Affiliates, in each case with whom the Buyer or an Authorised Recipient comes into contact, or in respect of whom the Buyer or an Authorised Recipient is provided information, in connection with the Proposed Transaction;

“**Secondary Information**” means paragraph (c) of the definition of Confidential Information; and

“**Senior Employee**” means any employee who has either a gross salary (excluding bonus) of over GBP 100,000 p.a., or a management role in the Group.

1.2 In this Agreement, unless expressly stated otherwise:

- (a) “subsidiary undertaking” and “parent undertaking” are each to be construed in accordance with section 1162 (and Schedule 7) of the Companies Act 2006 and, for the purposes of this definition, a “subsidiary undertaking” shall include any person the shares or ownership interests in which are subject to security and where the legal title to the shares or ownership interests so secured are registered in the name of the secured party or its nominee pursuant to such security.
- (b) references to a “person” includes any individual, partnership, body corporate, corporation sole or aggregate, state or agency of a state, and any unincorporated association or organisation, in each case whether or not having separate legal personality;
- (c) words introduced by the word “other” shall not be given a restrictive meaning because they are preceded by words referring to a particular class of acts, matters or things; and
- (d) general words shall not be given a restrictive meaning because they are followed by words which are particular examples of the acts, matters or things covered by the general words and the words “includes” and “including” shall be construed without limitation.

2. DUTY OF CONFIDENTIALITY

- 2.1 The Buyer and each Authorised Recipient who receives Confidential Information will hold the Confidential Information in strict confidence and shall not use, disclose, reproduce or distribute any Confidential Information in any way (whether in whole or in part, directly or indirectly) except to the extent reasonably necessary for evaluating, negotiating, financing, advising on and/or implementing the Proposed Transaction, and provided any disclosure, reproduction or distribution may only be to Authorised Recipients or with the prior written consent of evoke or otherwise as permitted by the terms of this Agreement.
- 2.2 The Buyer and each Authorised Recipient shall not make, permit or assist any other person to make any public announcement in relation to the Proposed Transaction except as permitted by Clause 3.2 below or otherwise with the prior consent of evoke.
- 2.3 The Buyer and each Authorised Recipient shall not use any Confidential Information to obtain a commercial, trading, investment, financial or other advantage over the Group or otherwise use Confidential Information to the detriment of any Group Company.
- 2.4 The Buyer and each Authorised Recipient who receives Confidential Information shall:
- (a) take all reasonable steps to ensure that the Confidential Information is protected against theft or unauthorised access with no lesser degree of care and no less robust security measures than those which would apply to the Buyer's or such Authorised Recipient's own confidential information; and
 - (b) provided it is legally permissible to do so, promptly inform evoke if the Buyer or such Authorised Recipient becomes aware or suspects that Confidential Information has been disclosed to or has come into the possession of any person in breach of this Agreement, with details of the full circumstances thereof which are then known to the Buyer or such Authorised Recipient and take such reasonable steps as evoke may request to retrieve such Confidential Information and/or protect it from further unauthorised disclosure.

3. PERMITTED DISCLOSURES

- 3.1 The undertakings in Clauses 2.1 and 2.2 will not apply to Confidential Information to the extent that:
- (a) the Confidential Information is in the public domain at the time of disclosure to the Buyer or an Authorised Recipient, or subsequently enters the public domain other than as a result of a breach of this Agreement by the Buyer or an Authorised Recipient (as if each Authorised Recipient were a party to this Agreement);
 - (b) when the Confidential Information was first disclosed to the Buyer or an Authorised Recipient, it was already in the lawful possession or knowledge of the Buyer or that Authorised Recipient and such person was not under any obligation of confidence in respect of it;
 - (c) after the Confidential Information was first disclosed to the Buyer or an Authorised Recipient, the Buyer or an Authorised Recipient receives the Confidential Information from a third party (excluding evoke, its Affiliates and its and their Representatives) who does not owe an obligation of confidence in respect of it; or
 - (d) the Confidential Information has been independently developed by the Buyer or an Authorised Recipient without use of, or reference to, any Confidential Information.

- 3.2 The Buyer and each Authorised Recipient may disclose Confidential Information to the extent required by any law, rule or regulation, legal process (including court order and subpoena), the rules and other requirements of any stock exchange, or by any governmental, supervisory, regulatory or self-regulatory authority to which the Buyer (or its Affiliates) or Authorised Recipient is subject (“**Applicable Laws**”), provided that the Buyer or Authorised Recipient shall, to the extent lawful and reasonably practicable in the circumstances:
- (a) promptly notify evoke of such requirement and consult with evoke on possible steps to avoid or limit disclosure and take any reasonable steps to agree the contents of the disclosure with evoke prior to making the disclosure;
 - (b) use reasonable endeavours to obtain assurances from the recipient of such disclosure that the Confidential Information being disclosed will be treated confidentially;
 - (c) co-operate with evoke, at evoke’s sole cost and expense, if evoke (acting reasonably) wishes to issue legal or other proceedings to challenge the validity of the requirement to disclose such Confidential Information;
 - (d) disclose only the minimum amount of information which is necessary to satisfy such requirement; and
 - (e) keep evoke fully and promptly informed of the full circumstances of any such disclosure and all related matters and developments.
- 3.3 The notification and cooperation requirements in Clauses 3.2(a) to 3.2(e) shall not apply in the case of a request or requirement of a regulatory or supervisory authority exercising its routine supervisory, examination or audit functions that is not specific to the Proposed Transaction or that does not request specific Confidential Information.

4. ALL AUTHORISED RECIPIENTS TO COMPLY WITH THIS AGREEMENT

- 4.1 The Buyer shall ensure that each Authorised Recipient is aware of the terms of this Agreement and complies with the terms of this Agreement as if such Authorised Recipient was itself a party to this Agreement.
- 4.2 The Buyer shall be liable for any breach of the terms of this Agreement by an Authorised Recipient as if the Buyer were the party that had breached them.

5. RETURN OR DESTRUCTION OF CONFIDENTIAL INFORMATION

- 5.1 Subject to Clause 5.2, if evoke requests the Buyer or any Authorised Recipient in writing, the Buyer and each Authorised Recipient shall as soon as reasonably practicable:
- (a) destroy or return to evoke (at the Buyer’s option), each original and every copy of any document (and other materials which are in a form reasonably capable of delivery) that contain Confidential Information (other than Secondary Information);
 - (b) ensure the destruction of all Secondary Information;
 - (c) use all reasonable endeavours to expunge all Confidential Information from any computer, word processor or other device containing Confidential Information; and
 - (d) confirm to evoke in writing that they have complied with paragraphs (a) to (c).
- 5.2 The Buyer and each Authorised Recipient may retain any Confidential Information to the extent:

- (a) required to do so by any Applicable Laws or its bona fide internal compliance or audit policies and procedures to which the Buyer or Authorised Recipient (as applicable) is subject; and/or
 - (b) contained in any electronic file created pursuant to any routine backup or archiving procedure so long as such file is not generally accessible beyond the need for disaster recovery or similar operations.
- 5.3 Any Confidential Information retained under Clause 5.2 shall continue to be held in compliance with the applicable terms of this Agreement.
- 6. NO REPRESENTATION OR WARRANTY TO THE BUYER**
- 6.1 The Buyer and each Authorised Recipient agrees that neither evoke nor any of evoke's Affiliates or its or their respective Representatives:
- (a) makes any representation or warranty as to the accuracy, reliability or completeness of any of the Confidential Information;
 - (b) shall have any liability to the Buyer or any Authorised Recipient or any other person resulting from the use of Confidential Information by the Buyer or any Authorised Recipient;
 - (c) shall have any obligation to provide Confidential Information or further Confidential Information, to update any Confidential Information, or to correct any inaccuracies in Confidential Information;
 - (d) shall have any obligation to enter into or continue discussions or negotiations in respect of the Proposed Transaction or to accept, review or consider any proposal or offer made by the Buyer or any Authorised Recipient; or
 - (e) shall owe any duty of care to the Buyer or any Authorised Recipient in connection with the Confidential Information or the Proposed Transaction.
- 6.2 Clause 6.1 does not exclude any liability for, or remedy in respect of, fraud or fraudulent misrepresentation.
- 7. RESTRICTIONS ON CONTACT WITH EMPLOYEES, CUSTOMERS, SUPPLIERS AND OTHERS**
- 7.1 All communications from the Buyer or any Authorised Recipients to evoke, evoke's Affiliates in relation to the Proposed Transaction should be directly addressed to Paolo Della Rovere (paolo.dellarovere@morganstanley.com) at Morgan Stanley, Daniel Ross (Daniel.Ross@rothschildandco.com) and Edward Duckett (Edward.Duckett@rothschildandco.com) or any other person identified by Morgan Stanley, Rothschild & Co or evoke for this purpose, and no one else.
- 7.2 For a period of twelve months after the date of this Agreement, the Buyer and each Authorised Recipient who actually receives Confidential Information (except where such Authorised Recipient is a finance provider (or potential finance provider), consultant or professional adviser in which case Clause 7.2(a) only shall apply) shall not directly or indirectly, without evoke's prior written consent:
- (a) subject to Clause 7.2(b), make or have any contact, in relation to the Proposed Transaction or any Confidential Information, with any shareholder, director, employee, customer, contractor or sub-contractor of, or supplier of, any Group Company, from time to time. However, this Clause 7.2(a) shall not apply:

- (i) to any contact by the Buyer or an Authorised Recipient to the extent that it is in the ordinary course of its existing business; or
- (ii) to the Buyer or an Authorised Recipient conducting general commercial, market or other similar due diligence on a no-names basis via a third party,

provided that no reference is made to any Confidential Information or to the Proposed Transaction; or

- (b) solicit, engage, employ (whether paid or unpaid) or offer to engage or employ, any Restricted Person. For these purposes, it does not matter whether such Restricted Person knows of any Confidential Information, or would commit a breach of such Restricted Person's contract of employment by reason of such Restricted Person leaving their employment. However, this Clause 7.2(b) shall not apply to a recruitment offer made to or employment of any person who contacts the Buyer or any Authorised Recipient solely on such person's own initiative or responds, without any form of approach or solicitation by or on behalf of the Buyer or an Authorised Recipient, to a general public advertisement made in the ordinary course of business and not specifically targeted at any Group Company or Restricted Person.

7.3 The undertakings in Clause 7.2 are intended for the benefit of evoke and each of evoke's Affiliates and apply to actions directly or indirectly carried out by or on behalf of the Buyer or any Authorised Recipients who actually receive Confidential Information.

7.4 The Buyer agrees that each of the restrictions and undertakings contained in Clause 7.2 are reasonable and necessary for the protection of the legitimate interests of evoke in the goodwill of the Group Companies and shall be construed as separate and independent undertakings.

8. RESTRICTIONS ON EXCLUSIVE FINANCING

Other than with the prior written consent of evoke, the Buyer and the Buyer's Authorised Recipients who actually receive Confidential Information in connection with the Proposed Transaction shall not directly or indirectly enter into any oral or written agreement, arrangement or understanding (or discussions that could lead to such an agreement, arrangement or understanding) regarding the engagement of a financing source on an exclusive basis or in such a manner that would otherwise prohibit or impede any other person from obtaining financing from such financing source for the purposes of a transaction equivalent to the Proposed Transaction. The Buyer and each such Authorised Recipient shall immediately release, or procure the immediate release of, any provider or potential provider of debt finance who has been so engaged or who has entered into any such agreement, arrangement or understanding prior to the date of this Agreement.

9. RESTRICTIONS ON FORMING A CONSORTIUM

Other than with the prior written consent of evoke, the Buyer and the Authorised Recipients shall not directly or indirectly enter into or continue, any discussions, negotiations, understandings or agreements with (or disclose any Confidential Information to) any person who may reasonably be regarded as a potential direct or indirect provider of equity finance, co-investor or consortium member in connection with the Proposed Transaction.

10. STANDSTILL

10.1 For a period of 12 months from the date of this Agreement, the Buyer shall not, and shall procure that none of its Affiliates and/or Authorised Recipients (except where such Authorised Recipient is a consultant or professional adviser and acting in such capacity) shall, either alone

or with other persons, directly or indirectly, whether alone or acting in concert with others, without evoke's prior written consent:

- (a) acquire, offer to acquire, procure, induce or encourage any other person to acquire any direct or indirect interest in any shares, debt or other securities of evoke Plc or any member of its Group (“**evoke Securities**”) or enter into any agreement, arrangement or understanding (whether legally binding or not) or do or omit to do any act as a result of which it or any person may acquire any direct or indirect interest in any evoke Securities;
- (b) subject to Clause 3.2, make, announce, procure or induce any other person to make or announce any firm offer, possible offer, invitation or solicitation for all or any interest in evoke Securities, or enter into any agreement, arrangement or understanding (whether legally binding or not), or do or omit to do any act as a result of which any person may become obliged to make or announce a firm offer, possible offer, invitation or solicitation for such an interest;
- (c) submit any proposal which because of its terms would be required to be made public by evoke Plc, or announce any proposal for any purchase, offer, tender, merger, consolidation, share exchange, restructuring, recapitalisation or similar transaction which in any case involves evoke Securities or any material undertakings, assets or business of evoke Plc;
- (d) take any step which might give rise to any obligation under evoke Plc's Articles of Association and/or the Code (to the extent applicable) or otherwise to make any sort of offer or tender for all or any part of the share capital of evoke;
- (e) enter into any acquisition or other business arrangement relating to evoke Plc of a nature similar to the Proposed Transaction or anything similar to it or any material part of it;
- (f) otherwise seek, alone or in concert with others, to control or influence the management, board of directors or policies or affairs of evoke Plc;
- (g) make or in any way participate, directly or indirectly, in any solicitation of proxies or votes or any attempt to influence votes from or by any holder of voting shares or other evoke Securities in connection with any vote of holders of evoke Securities or requisition or join in requisitioning or attempt to induce any other person to requisition any general meeting of evoke Plc;
- (h) enter into any agreement or arrangement (whether or not legally binding) with any person relating to or connected with any of the foregoing; or
- (i) procure to be done any of the above.

10.2 The restrictions in Clause 10.1 shall cease to apply on the earlier of:

- (a) the Buyer or one of its Affiliates, or any person acting in concert with any of them, announcing a firm intention to make an offer for evoke Plc which is recommended by the board of directors of evoke Plc (and for the avoidance of doubt, such an announcement is not prohibited by these restrictions); or
- (b) a third party (not acting in concert with the Buyer or any of its Affiliates) announcing a firm intention to make an offer to acquire evoke Plc.

- 10.3 The restrictions in Clause 10.1 shall not apply to:
- (a) dealings in any interest in shares or other securities of evoke Plc by any connected fund manager or principal trader (each as defined in the Code) of the Buyer or any of its Affiliates; or
 - (b) the acquisition or disposals of interest in securities of evoke Plc in the ordinary course of business by any person which is an investment banking and/or full service security firm, provided that such activities did not arise, directly or indirectly, from the instructions of, or otherwise in conjunction with or on behalf of, the Buyer or any of its Affiliates, and that no Confidential Information shall be used in connection with such activities.
- 10.4 If the Buyer or any person acting in concert with it acquires an interest in securities of evoke Plc in contravention of this Agreement, the Buyer must dispose or use reasonable endeavours to procure the disposal of such interest within 30 days of it becoming lawful to do so. Pending such disposal, the Buyer shall not, and shall use reasonable endeavours to procure that each of its persons acting in concert shall not, exercise any rights attached to any such interest in securities.
- 10.5 In this Clause 10, references to an “offer” and “acting in concert” shall be interpreted in accordance with those terms as defined in the Code.

11. MARKET ABUSE

- 11.1 The Buyer acknowledges and agrees that the Proposed Transaction and some or all of the Confidential Information may be inside information relating to the Group and/or the securities of evoke Plc for the purposes of Part V of the Criminal Justice Act 1993 (the “CJA”) and/or the United Kingdom’s assimilated version of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, which is part of United Kingdom law by virtue of the European Union (Withdrawal) Act 2018 (“UK MAR”) and that it shall comply with its obligations under UK MAR (and any equivalent applicable legislation) in respect of such Confidential Information including, without limitation, that neither it nor any of its Authorised Recipients should, or should direct any other person to:
- (a) deal or procure any dealing in securities that are price-affected securities (as defined in the CJA) in relation to any inside information, encourage another person to deal in price-affected securities or disclose any inside information except as permitted by the CJA before the inside information is made public;
 - (b) engage or attempt to engage in insider dealing (as defined in UK MAR), recommend that another person engage in insider dealing or induce another person to engage in insider dealing on the basis of any inside information;
 - (c) unlawfully disclose any inside information (as defined in UK MAR); or
 - (d) engage or attempt to engage in behaviour based on any inside information which would amount to market manipulation (as defined in UK MAR).
- 11.2 In relation to Confidential Information which constitutes inside information, the Buyer consents to being made an insider within the meaning of the CJA and UK MAR and shall bring to the attention of its Authorised Recipients their obligations and liabilities in relation to inside information under the CJA and UK MAR

12. DURATION AND TERMINATION

This Agreement shall continue in full force and effect until the earlier of:

- (a) entry into a definitive written agreement by the Buyer or the Buyer's Affiliates relating to the Proposed Transaction containing separate confidentiality obligations; or
- (b) the second anniversary of the date of this Agreement,

upon which this Agreement shall be of no further effect except for any rights or liabilities that have accrued prior to termination.

13. ACTING AS PRINCIPAL

The Buyer confirms that the Buyer is acting as principal and not as agent, nominee or broker for any other person.

14. NO WAIVER OF PRIVILEGE

Access to the Confidential Information is granted to the Buyer and the Authorised Recipients without any waiver by evoke or any of evoke's Affiliates or its or their respective Representatives of confidentiality or legal professional privilege or common interest privilege which attaches to any of the Confidential Information.

15. ASSIGNMENT

- 15.1 The Buyer may not assign this Agreement or any of its rights or obligations under this Agreement without the prior written consent of evoke.
- 15.2 The rights of evoke under this Agreement may be assigned or transferred in whole or in part to any Affiliate of evoke, or third party which acquires all, or a material part, of the issued share capital, business or assets of evoke and that such Affiliate of evoke or third party shall, upon such assignment or transfer, be entitled to enforce this Agreement to the same extent and in the same manner as if such party were evoke.
- 15.3 If the rights of evoke under this Agreement are assigned or transferred in whole or part to a third party, evoke shall notify the Buyer of such assignment or transfer as soon as reasonably practicable.

16. WAIVER AND VARIATION

- 16.1 No variation or amendment of this Agreement shall be valid unless it is in writing and duly executed by or on behalf of all of the parties hereto.
- 16.2 No delay or failure by any party to require performance of any provision of this Agreement shall affect its right to enforce such provision at a later time.
- 16.3 A waiver of any right or remedy under this Agreement shall only be effective if given in writing and shall not be deemed a waiver of any subsequent breach or default.

17. INVALIDITY

If and to the extent that any provision of this Agreement is held to be invalid or unenforceable, it shall be given no effect and shall be deemed not to be included in this Agreement, but everything else in this Agreement shall continue to be binding.

18. RIGHTS OF THIRD PARTIES

- 18.1 Other than evoke's Affiliates, each of which shall be entitled to enforce this Agreement as if it were a party, a person who is not a party to this Agreement shall have no right under the Contracts (Rights of Third Parties) Act 1999 to enforce any of its terms.
- 18.2 Each party represents to the other that their respective rights to terminate, rescind or agree any amendment, variation, waiver or settlement under this Agreement are not subject to the consent of any person that is not a party to this Agreement.

19. ENTIRE AGREEMENT AND REMEDIES

- 19.1 The rights, powers, privileges and remedies provided in this Agreement are cumulative and not exclusive of any rights, powers, privileges or remedies provided by law.
- 19.2 This Agreement contains the whole agreement between evoke and the Buyer in respect to the protection of the Confidential Information and supersedes all prior communications and understandings with respect thereto.
- 19.3 Without prejudice to any other rights or remedies that evoke or any Group Company may have, the Buyer acknowledges and agrees that:
- (a) evoke and its Affiliates may be irreparably harmed by any breach of the terms of this Agreement and that damages alone may not be an adequate remedy; and
 - (b) the remedies of injunction, specific performance and other equitable relief, or any combination of these remedies, may be available to evoke and its Affiliates for any breach of this Agreement.

20. COUNTERPARTS

This Agreement may be executed in any number of counterparts. Each counterpart shall constitute an original of this Agreement but all the counterparts together shall constitute one and the same instrument.

21. GOVERNING LAW AND JURISDICTION

- 21.1 This Agreement and any non-contractual rights or obligations arising out of or in connection with it shall be governed by and construed in accordance with English law.
- 21.2 The parties irrevocably agree that the courts of England and Wales shall have exclusive jurisdiction to settle any Disputes, and waive any objection to proceedings before such courts on the grounds of venue or on the grounds that such proceedings have been brought in an inappropriate forum.
- 21.3 For the purposes of Clause 21.2, "**Dispute**" means any dispute, controversy, claim or difference of whatever nature arising out of, relating to, or having any connection with this Agreement, including a dispute regarding the existence, formation, validity, interpretation, performance or termination of this Agreement or the consequences of its nullity and also including any dispute relating to any non-contractual rights or obligations arising out of, relating to, or having any connection with this Agreement.

[Remainder of page intentionally left blank]

This Agreement has been entered into on the date stated at the beginning of it.

For and on behalf of William Hill Organization Limited



.....
Sean Wilkins
Authorised signatory

For and on behalf of Intralot Holdings UK Ltd

.....
Authorised signatory

This Agreement has been entered into on the date stated at the beginning of it.

For and on behalf of William Hill Organization Limited

.....

Authorised signatory

For and on behalf of Intralot Holdings UK Ltd



.....
Matt Hill
Authorised signatory